{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fstartup-insider.simplecast.com%2Fepisodes%2Fip-transfer-berliner-modell-biotech-6JKtpZPO","width":444,"version":"1.0","type":"rich","title":"IP-Transfer: Der unsichtbare Dealbreaker in der Frühphase – Ute Mercker (IBB Ventures)","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/97a167f4-fd47-43be-a3f7-e056c5f93dd5/f684ff73-cc9d-441d-bcb5-6d9d3d7e8c04/ute.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/6aacad78-d77c-4bfd-ba99-9ed9f9fe4620\" height=\"200\" width=\"100%\" title=\"IP-Transfer: Der unsichtbare Dealbreaker in der Frühphase – Ute Mercker (IBB Ventures)\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Warum scheitern Biotech-Ausgründungen am IP-Transfer? Ute Mercker von IBB Ventures erklärt das neue Berliner Modell für Technologietransfer und wie Berlin zum „Boston an der Spree\" werden kann."}